Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) represented a move of -8.48 percent or $-0.03 per share and closed its previous day trading session at $2.54. 6.44 Million Shares were traded in the last trading session with an Average Volume of 1.5 Million Shares. The stock currently has a Market Capitalization of 284.6 Million.
CATALYST PHARMACEUTICAL PARTNERS, INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven’s patent portfolio in the US relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven’s vigabatrin-related foreign patents or patents pending worldwide. The Company’s initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted Fast Track status by the U.S. Food & Drug Administration for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs.
The stock traded between $2.18 and $4.51 over 1-Year time period showing its price to sales ratio of 0. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-20.78 and 200-Day Simple Moving Average of $-17.88. Its Price to Free Cash Flow is 0 and Price to Book of 4.09.
Analyst’s recommended the stock as 1.8 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) reported its Actual EPS of $-0.08/share. The analysts offering Earnings Estimates for the company were believing that Catalyst Pharmaceuticals, Inc. could bring EPS of $-0.08/share. The difference between Actual EPS and Estimated EPS was 0 Percent. Thus showing an Earnings Surprise of 0 Percent.
Consolidated Communications Holdings, Inc. (NASDAQ:CNSL)
In the last trading session, Consolidated Communications Holdings, Inc. (NASDAQ:CNSL) added its value by -0.43% closing at the price of $13.76. The stock currently has market capitalization of 984.67 Million, with average volume of 625.99 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Consolidated Communications Holdings, Inc. (NASDAQ:CNSL) is showing beta of 0.59. This particular value of beta suggests that Consolidated Communications Holdings, Inc. (NASDAQ:CNSL) has historically moved 59% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Consolidated Communications Holdings, Inc. (NASDAQ:CNSL) is at $-0.72.
The stock currently has RSI of 58.95. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Consolidated Communications Holdings, Inc. offers a wide range of telecommunications services including local and long distance telephone, Digital Phone, High-Speed Internet access and Digital TV to individuals and businesses in Illinois, Pennsylvania, and Texas. The company also offers telephone directory publishing services, wholesale transport services, billing and collection services, inside wiring services, and maintenance services. Consolidated Communications Holdings, Inc. is headquartered in Mattoon, Illinois.
Consolidated Communications Holdings, Inc. (NASDAQ:CNSL) topped its 52-week high price of $14.55 on 11/27/18 and 52-Week Low Price of $10.31 on 04/04/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 3.31% and monthly volatility of 3.79% respectively.